Updated: February 5, 2026
Jatenzo Access Update: What Patients Need to Know in 2026
Author
Peter Daggett

Summarize with AI
- Is Jatenzo in a Drug Shortage in 2026?
- The Injectable Testosterone Shortage Is Still Affecting TRT Patients
- Regulatory Update: Blood Pressure Boxed Warning Removed in July 2025
- Pricing Update in 2026
- Insurance Coverage Trends in 2026
- Pharmacy Availability: What to Expect
- What Should Patients Do Right Now?
Jatenzo isn't in official shortage, but access remains challenging for many patients in 2026. Here's the latest on availability, pricing, insurance coverage, and your options.
If you take Jatenzo (testosterone undecanoate) for testosterone replacement therapy, you may be wondering what the access situation looks like in 2026. This update covers everything you need to know: availability, pricing, insurance coverage changes, regulatory updates, and practical tips for filling your prescription.
Is Jatenzo in a Drug Shortage in 2026?
No. As of 2026, Jatenzo is not on the FDA's official drug shortage list. Oral testosterone undecanoate capsules — including Jatenzo, Tlando, and Kyzatrex — are available from manufacturers. The product is being made and distributed.
However, "available from manufacturers" does not mean "easy to fill at your pharmacy." Access challenges for Jatenzo in 2026 stem from a different set of problems: cost, pharmacy stocking, and insurance access barriers.
The Injectable Testosterone Shortage Is Still Affecting TRT Patients
The broader testosterone landscape in 2026 is shaped by the ongoing injectable testosterone cypionate shortage. Testosterone Cypionate injections — both brand-name Depo-Testosterone and generics — have been in intermittent shortage since early 2023. Supply has gradually improved but has not fully normalized as of early 2026.
This shortage is relevant to Jatenzo patients because: (1) some injectable TRT patients are being switched to oral formulations, increasing demand for Jatenzo; and (2) the overall difficulty of accessing testosterone in any form has raised awareness of the complexity of TRT access.
Regulatory Update: Blood Pressure Boxed Warning Removed in July 2025
A significant regulatory update: in July 2025, the FDA removed the boxed warning about blood pressure increases from Jatenzo's prescribing information. This is notable because the boxed warning had previously been one of the most prominent safety cautions associated with the drug, and had affected prescribing patterns.
Important: Blood pressure monitoring is still required. Jatenzo can still raise blood pressure, and periodic monitoring is still part of the prescribing guidelines. The removal of the boxed warning reflects a change in how this risk is classified — not the elimination of the risk itself.
Pricing Update in 2026
Jatenzo remains one of the more expensive testosterone formulations on the market in 2026. Here's the current pricing landscape:
Retail cash price: $1,314–$1,658+ per 60 capsules (30-day supply at 237 mg)
GoodRx coupon: As low as ~$1,101 for 60 capsules at 237 mg
SingleCare coupon: As low as ~$1,013 for 60 capsules at 237 mg
Jatenzo Copay Card (commercially insured): As little as $0/month; covers up to $393 per 30-day fill for 12 fills/year
Cash patient program price: $185/month through contracted network pharmacies
Coverage-denied program: $150/month at contracted pharmacies for commercially insured patients whose PA was denied
Insurance Coverage Trends in 2026
Insurance coverage for Jatenzo continues to be a significant obstacle:
Most commercial plans require prior authorization and step therapy before approving Jatenzo
Medicare Part D plans generally do not cover Jatenzo without a formulary exception
Medicaid coverage varies by state and is generally limited for brand-name specialty testosterone
TRICARE and other government programs do not qualify for the Tolmar copay card
Pharmacy Availability: What to Expect
Jatenzo is not a drug that most pharmacies carry on their shelves. It's a specialty brand-name product with limited volume. Patients should expect to:
Call multiple pharmacies before finding one with stock or willing to special-order
Wait 1–3 business days if a pharmacy needs to special-order the medication
Consider working with a specialty pharmacy through their contracted network for the manufacturer cash pricing
What Should Patients Do Right Now?
Here are the most important steps for Jatenzo patients in 2026: Confirm your prior authorization is current and doesn't expire before your next refill. Apply for the Jatenzo Copay Card if you have commercial insurance. Use medfinder to locate pharmacies near you that can fill your prescription. If insurance barriers are too significant, ask your doctor about the Tolmar Patient Assistance Program.
For a full guide to cutting your Jatenzo costs, see our article on how to save money on Jatenzo in 2026.
Frequently Asked Questions
Yes. Jatenzo is not on the FDA drug shortage list and is still being manufactured by Tolmar, Inc. It is generally available through pharmacies that stock it or can special-order it. The main challenges are cost and insurance access, not supply.
Yes. In July 2025, the FDA removed the boxed warning about blood pressure increases from Jatenzo's prescribing information. Blood pressure monitoring is still required and blood pressure elevation remains a listed warning — the change reflects how the risk is categorized, not the elimination of the risk.
The retail cash price for Jatenzo is $1,314–$1,658+ per month (60 capsules at 237 mg). With GoodRx, the price drops to around $1,101. For commercially insured patients, the Jatenzo Copay Card can reduce costs to $0/month. Cash patients using Tolmar's program can pay $185/month at contracted pharmacies.
Generally no. Most Medicare Part D plans do not include Jatenzo on their formulary. You may request a formulary exception with documentation from your prescriber, but approval is not guaranteed. The Jatenzo Copay Card is also not valid for Medicare patients.
Tolmar offers patient assistance through the Jatenzo Support program, which includes a copay card for commercially insured patients ($0/month up to $393 per fill), a coverage-denied rate of $150/month, and a cash patient price of $185/month through contracted pharmacies. Additional PAP options may be available for uninsured patients — contact Tolmar directly for eligibility details.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Jatenzo also looked for:
More about Jatenzo
36,651 have already found their meds with Medfinder.
Start your search today.





